EUCTR2011-005248-81-IT进行中（未招募）不适用
Differentiated thyroid cancer: metabolic radiotherapy with high activity of radioiodine calculated by individual pre-therapy dosimetry - High activity of radioiodine
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2011年12月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- diagnosis of differentiated thyroid carcinoma - ECOG performance status of grade 0 or 1 - Age between 18 and 80 years old - Life expectancy of 3 months at least - Fertile women compliance to adopt contraceptive methods for at least 6 months after treatment -Adequate medullar reserve and renal functionality - Eventual second tumor in complete remission for 5 years at least - Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Presence of serious concomitant non neoplastic diseases, not adequately controlled - Pregnancy or breast feeding - Impossibility to follow-up - Concomitant use of nephrotoxic drugs - Surgery or radiotherapy within 2 weeks from beginning of treatment - Pulmonary diffused micrometastases - Extensive skeletal metastases
研究者
相似试验
已完成
不适用
Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PETthyroid cancerDifferentiated tyroid carcinoma1004373910014713NL-OMON38034Antoni van Leeuwenhoek Ziekenhuis100
暂停
不适用
Improving the diagnostic strategy of patients with recurrent differentiated thyroid cancer with PET/CT.Differentiated thyroid cancerI-124 PET/CTFDG PET/CTNL-OMON27626The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital100
进行中（未招募）
1 期
Personalized therapy of metastatic thyroid cancer: biological characterization and optimization with 124I PET dosimetrymetastatic thyroid cancerMedDRA version: 20.0Level: PTClassification code 10076603Term: Poorly differentiated thyroid carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002548-21-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI50
尚未招募
不适用
Detection of thyroid cancer and central lymph node metastases using bevacizumab-IRDye800CW enhanced Molecular Fluorescence Guided Surgery1004373910014713thyroid cancerNL-OMON51075niversitair Medisch Centrum Groningen32
尚未招募
不适用
A study on thyroid cancer, detecting circulating tumor cells and BRAF gene mutations through preoperative blood tests, and comparing the identified BRAF gene mutations to postoperative pathological tissue BRAF gene mutationsKCT0005820Seoul National University Bundang Hospital20